Welcome to the Pentracor GmbH

Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.

In heart attack and stroke, the C-reactive protein (CRP) leads to an increase of the primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.

The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.

More about the treatmentAsk questions

PentraSorb® CRP

Since November 2014 Pentracor GmbH is responsible and certified for the production and distribution of CRP adsorbers according to EN ISO 13485. The PentraSorb® CRP is an adsorber for the selective depletion of C-reactive protein (CRP).

CRP Adsorber

In the case of organ damage (e.g. heart attack or stroke), CRP marks cells capable of regeneration, which are then eliminated by the immune system. This increases the primary damage.

With the help of the PentraSorb® CRP can be removed from the blood with the aim of reducing this damage.

Read More

CRP apheresis

In CRP apheresis, CRP is selectively removed from the patient's blood plasma.

The application of PentraSorb® CRP is comparable to dialysis and can be performed in an outpatient or inpatient setting.

During the treatment, blood plasma is passed through the PentraSorb® CRP, which then selectively removes CRP from it.

Read More


In principle, CRP reduction can induce therapeutic benefits in a number of acute and chronic diseases.

PentraSorb® CRP is a potential therapeutic option for diseases where elevated CRP levels are associated with a poor prognosis.

Read More


Neuer Case Report über einen jungen COVID-19-Patienten erschienen

Pentracor GmbH veröffentlich Jahresabschluss 2020 und erzielt gute Fortschritte im ersten Halbjahr 2021

Hennigsdorf, 28.07.2021 – Das Medizintechnik-Unternehmen Pentracor GmbH mit Sitz in Hennigsdorf bei
Berlin hat seinen Jahresabschluss 2020 veröffentlicht. Das Geschäftsjahr war geprägt vom Roll-out des vom
Unternehmen entwickelten und zertifizierten Medizinprodukts PentraSorb® CRP sowie der Initiierung und Durchführung von klinischen Studien, um die Akzeptanz für die CRP-Apherese in der Behandlung von Krankheiten, die mit einer akuten Entzündung wie Herzinfarkt einhergehen, zu erhöhen.

Article about the CAMI-1 study published in "Intensiv-News"


In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.

Pentracor nominated for the "Zukunftspreis Brandenburg" 2021

Twelve companies have been nominated by the main jury for the "Zukunftspreis Brandenburg" 2021. Six prize winners and one company as a special prize winner will be awarded Brandenburg's most important business prize in the final on November 12 at the Airport Center Berlin Schönefeld. Pentracor GmbH, based in Hennigsdorf, is among the nominees. "We are very honored by the nomination," said Pentracor CEO Dr. Ahmed Sheriff.

Interview with Dr. Ahmed Sheriff on CRP apheresis for COVID-19 patients

ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.

ZDF reports on CRP apheresis as salvation for COVID-19 patients


ZDF has reported on CRP apheresis treatment for COVID-19 patients.

At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.